STOCK TITAN

Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

On July 6, 2021, Translate Bio (Nasdaq: TBIO) granted non-qualified stock options for 177,400 shares to nine new employees as part of its 2021 Inducement Stock Incentive Plan. The options have an exercise price of $28.60 per share, matching the closing stock price on the grant date, and vest over four years. Translate Bio is focused on developing mRNA therapeutics, especially for pulmonary diseases like cystic fibrosis, and is exploring a range of treatments including mRNA vaccines through a collaboration with Sanofi Pasteur.

Positive
  • Granting stock options may attract and retain skilled employees.
  • The company is developing mRNA therapeutics, focusing on cystic fibrosis, which could lead to significant market opportunities.
Negative
  • The stock options were granted at a time when the stock price is subject to market fluctuations, posing potential financial risk.
  • The reliance on stock options for employee compensation may lead to shareholder dilution.

LEXINGTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on July 6, 2021, the Company granted non-qualified stock options to purchase an aggregate of 177,400 shares of the Company’s common stock to nine new employees. These grants were made pursuant to the Company’s 2021 Inducement Stock Incentive Plan, were approved by the Company’s Inducement Grant Subcommittee of the board of directors, and were made as a material inducement to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

The stock options have an exercise price of $28.60 per share, equal to the closing price of Translate Bio’s common stock on July 6, 2021. Each stock option has a ten year term and vests over four years, with 25% of the shares underlying the option vesting on or by July 6, 2022 and in thirty-six equal monthly installments thereafter as to the remaining shares. The vesting of each grant is subject to the employee’s continued service with the Company through the applicable vesting date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2021 Inducement Stock Incentive Plan.

About Translate Bio
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases with a lead pulmonary candidate being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio also believes its technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or protein degradation. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration and license agreement with Sanofi Pasteur. For more information about the Company, please visit www.translate.bio or on Twitter at @TranslateBio.

  
Investor Relations
Teri Dahlman
tdahlman@translate.bio
Media Relations
Maura Gavaghan
mgavaghan@translate.bio

FAQ

What is the recent stock options grant by Translate Bio (TBIO)?

Translate Bio granted non-qualified stock options for 177,400 shares to nine new employees on July 6, 2021, as part of its 2021 Inducement Stock Incentive Plan.

What is the exercise price for the stock options granted by TBIO?

The exercise price for the stock options is $28.60 per share, equal to the closing price on July 6, 2021.

How long do the stock options granted by Translate Bio last?

The stock options have a ten-year term and vest over four years.

What is Translate Bio focusing on in its developments?

Translate Bio is primarily focused on developing mRNA therapeutics for pulmonary diseases, such as cystic fibrosis.

Is Translate Bio collaborating with any other companies?

Yes, Translate Bio is collaborating with Sanofi Pasteur to develop mRNA vaccines for infectious diseases.

TELESIS BIO INC

OTC:TBIO

TBIO Rankings

TBIO Latest News

TBIO Stock Data

5.89M
69.98M
30.67%
33.17%
1.68%
Medical Devices
Laboratory Analytical Instruments
Link
United States of America
SAN DIEGO